| Date | Subject | Details |
|---|---|---|
| 2025/08/13 | Announcement on Election Results of Directors for Subsidiary TBG Diagnostics Ltd | 20250813-2 |
| 2025/08/13 | Announcement on Election Results of Directors for Subsidiary TBG Diagnostics Ltd | 20250813-1 |
| 2025/08/11 | Announcement of board meeting approved the consolidatedfinancial statements 2025Q2 | 20250811 |
| 2025/08/05 | The Progress Update of the New Drug under Development, OBP-301 | 20250805 |
| 2025/08/04 | Announcement of the date of the board of directors meeting for the second quarter of 2025 financial report | 20250804 |
| 2025/07/07 | Announcement of Final Non-Prosecution DecisionRendered by the Taiwan High Prosecutors OfficeRegarding Company Executives | 20250707 |
| 2025/06/24 | The Progress Update of the New Drug underDevelopment, OBP-301 | 20250624 |
| 2025/06/06 | Company has withdrawn its US FDA IND application for PhaseI/II human clinical trials of allogeneic natural killer cells (Magicell-NK) | 20250606 |
| 2025/06/05 | Announcement of Important Resolutions fromthe 2025 Shareholders’ Meeting of the Company | 20250605 |
| 2025/05/23 | The Progress Update of the New Drug under Development, OBP-301 | 20250523 |
| 2025/05/15 | Our company has applied to U.S. Food and Drug Administration (US FDA) for Phase I/II human clinical trials of allogeneic natural killer cells (Magicell-NK) | 20250515 |
| 2025/05/13 | The Progress Update of the New Drug under Development, OBP-301 | 20250513 |
| 2025/05/12 | The Company’s 2025Q1 consolidated financialstatements have been approved by the Board ofDirectors | 20250512 |
| 2025/05/02 | Announcement of the date of the board ofdirectors meeting for the first quarter of 2025financial report | 20250502 |
| 2025/03/26 | Japan Patent Granted for OBP-301Administration Method | 20250326 |
| 2025/03/18 | The Progress Update of the New Drugunder Development, OBP-301 | 20250318 |
| 2025/03/10 | The Company’s board of directors resolvedto convene 2025 General Shareholder’s meeting | 20250310-3 |
| 2025/03/10 | The Board of Directors has resolved not to distributedividends | 20250310-2 |
| 2025/03/10 | The Company’s 2023 consolidated financial statements have been approved by the Board of Directors | 20250310-1 |
| 2025/03/03 | Announcement about resignation of the Company’s Chief Scientific Officer | 20250303 |
| 2025/02/27 | Announcement of the date of the board ofdirectors meeting for the fourth quarter of 2024financial report | 20250227 |
| 2025/02/02 | Reporting the Result of PI-initiated Phase IClinical Trial for OBP-301-Chemoradiation CombinationTherapy in ASCO (Corrected) | 20250202 |
| 2025/01/24 | Reporting the Result of PI-initiated Phase IClinical Trial for OBP-301-Chemoradiation CombinationTherapy in ASCO | 20250124 |
| 2025/01/15 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Changhua Christian Hospital | 20250115 |
